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Guest Editorial
Appropriate Use of Clopidogrel
CYRUS R KUMANA, BERNARD MAN-YUNG CHEUNG, IJ LAUDER*
From Department of Medicine and Department of Statistics & Acturial Science*, The University of Hong Kong,
Queen Mary Hospital, Hong Kong

Clopidogrel (Plavix®) is an orally administered
pro-drug, whose pharmacology and therapeutic role has
been extensively reviewed in recent publications.1-5 In
essence, it results in selective and irreversible
antagonism of ADP-induced platelet aggregation. Such
aggregation normally results in the surface expression
of platelet glycoprotein (GP) IIb/IIIa receptors, which
facilitate fibrinogen binding as well as consequential
further platelet aggregation – the final common pathway
of vascular occlusion. Specific cytochrome P450 enzymes
are thought to generate the responsible active metabolite
(believed to persist transiently). However, dosage
adjustment is not recommended in hepatic impairment
(unless severe) and drug-drug interactions and coadministration with meals are believed to be unimportant.
Based on clinical trials of outcome, several orally
administered anti-platelet drugs have proven efficacy
(mainly for secondary prevention) in the context of
coronary events, ischaemic strokes and peripheral
vascular disease. These include: (1) aspirin, (2)
dipyridamole (Persantin), (3) ticlopidine (Ticlid), and
(4) clopidogrel (Plavix) all of which have important
adverse effects.6,7 Dipyridamole gives rise to headaches,
postural lightheadness, and gastrointestinal symptoms
(mainly diarrhea & nausea). The relatively common
adverse effects of ticlopidine (neutropenia,
thrombocytopenia, hepatitis and diarrhea) pose a
problem. With clopidogrel, adverse effects are
comparable to aspirin and certainly less frequent and
less severe than with ticlopidine. However, it too has
been linked to thrombotic thrombocytopenic purpura
(even resulting in death).8 Moreover, clopidogrel's long
term safety has not been established, nor are the risks
known among ethnic groups (including the Chinese) that
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are believed to be more prone to bleeding.
Only a few of the relevant clinical trials have
compared different anti-platelet drug treatment
intervention regimes to each other with respect to
outcomes. In the multi-centre CAPRIE (Clopidogrel
v Aspirin in Patients at Risk of Ischaemic Events)
double blind randomised controlled trial, clopidogrel or
aspirin (both 75 mg/day) were given to 19,185
atherosclerotic patients. 9 The protocol entailed
randomisation to three groups viz: Stroke, MI &
Peripheral arterial disease (PAD), and follow up for 1-3
years. The ensuing results are outlined below (Table 1).

Table 1. Primary outcome (myocardial infarction,
ischaemic stroke or vascular death)
Clopidogrel
Placebo

Event ensued
939
1021

No event
8614
8846

Total
9553
9546

The relative risk reduction (RRR) was 8.7%
(adjusted) with a 95% CI of 0.3-16.5%; P<0.05. The
more meaningful absolute risk reduction (ARR)
amounted to 0.86% over an average of 1.91 years. The
corresponding number needed to treat (NNT) to prevent
one patient experiencing an adverse outcome event over
that period was 115 (95% CIs 57-∞), which is equivalent
to an NNT/year of 220. Unexpectedly the benefit was
largely confined to patients with prior peripheral arterial
disease and stroke.
That drugs such as clopidogrel, which inhibit ADP
induced platelet aggregation may complement the
antiplatelet activity of aspirin (a cyclo-oxygenase
inhibitor) without unduly compromising safety, has
kindled interest in using them in combination. In the
multi-centre CURE (Clopidogrel in Unstable angina to
prevent Recurrent Events) trial, 10,11 12,562 patients
taking aspirin (75-325 mg/day) ± heparin, β-blockers,
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statins or calcium channel blockers – were randomised
to treatment with clopidogrel (75 mg/day) or placebo
for 3-12 (mean of 9) months. The RRR (for
cardiovascular death, non-fatal stroke or MI) was 20%
(adjusted) with a 95% CIs of 10-28%. The corresponding
NNT was 47 or 35/year. Evidently, the relative risk (RR)
of major bleeding was 1.38% (95% CIs 1.13-1.67), there
being one such additional episode for every 99 patients
treated with clopidogrel and aspirin (as opposed to
aspirin alone) over this period of time (or 74/year).
However, there was no excess in bleeds causing fatality,
strokes or need for surgical intervention. Notably, for
many of the patients undergoing revascularisation
procedures, study medication was temporarily
interrupted or given as open label therapy. In the overall
analysis, it was estimated that for every 1000 patients
treated for 9 months, 28 major events would be
prevented at a cost of 3 patients having life-threatening
bleeds and 3 more requiring transfusions.12
In 2001, clopidogrel was among the Hong Kong
Hospital Authority's top 20 items of expenditure on
pharmaceuticals, having increased in popularity
dramatically over the last year. Compared to aspirin,
currently it is many orders of magnitude more expensive.
Thus, substituting clopidogrel for aspirin, treatment of
220 patients for 1 year would be expected to prevent 1
of them from suffering an ischaemic event, but
depending on which formulation was replaced corresponding drug costs could increase by between 46
to 205 fold (Table 2). In mitigation, use of clopidogrel
may involve cost-savings in terms of slightly reduced
numbers of patients having revascularisation procedures
and the associated use of much more expensive drugs
(GP IIb/IIIa receptor blockers).
Hitherto the conventional indications for
prescribing clopidogrel were mainly confined to: (1)

Table 2. Drug acquisition costs
Drug
Clopidegrel
Ticlopidine
Dipyridamole

Typical dosage/day
75 mg
250 mg
25 mg
75 mg

Aspirins
Asprin
Dispersable aspirin
Cartia
SR Cardiprin

2

80 mg
300 mg
100 mg
100 mg

HK$ (Nov 2001)
12.30
7.25
0.09
0.20
0.06
0.27
0.23
0.18

cover (together with aspirin) for patients undergoing
angioplasty and/or stenting procedures, and (2) as a
substitute for aspirin for individuals in whom the latter
drug was contraindicated or poorly tolerated. If the daily
cost of clopidogrel treatment (currently up to 205 fold
that of aspirin) is not an issue, it may also be reasonable
to use it: (3) instead of aspirin in all ischaemic
cardiovascular disease states, and (4) in combination
with aspirin for patients with unstable angina. However,
the long-term safety of this agent is not known.
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